演題詳細

一般口演 / Oral Session

一般口演 1 (Oral Session 1) :鉄代謝 (Iron Metabolism)

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第3会場 / Room No.3 (さっぽろ芸文館 3F 蓬莱)
座長・司会
川端 浩 (Hiroshi Kawabata):1
1:京都大学 血液・腫瘍内科学
 
前へ戻る

C.E.R.A. suppressed hepcidin levels through activation of erythropoiesis

演題番号 : OS-1-3

野口 真理子 (Mariko Noguchi-Sasaki):1、佐々木 雄亮 (Yusuke Sasaki):1、松尾 有佳里 (Yukari Matsuo):1、倉澤 光江 (Mitsue Kurasawa):1、佐藤 扶美 (Fumi Sato-Inomata):1、萬 啓悟 (Keigo Yorozu):1、下中 靖 (Yasushi Shimonaka):1

1:Product Research Dept., Chugai Pharmaceutical Co.,Ltd., Kamakura, Japan

 

Background:Hepcidin is a key hormone of systemic iron metabolism. Iron, erythropoiesis and inflammation are known to regulate hepcidin production. We investigated the mechanism of hepcidin suppression after continuous erythropoietin receptor activator (C.E.R.A.) treatment with or without iron intervention in mice.
Methods:C57BL/6N mice were administered dextran iron (0.5 mg/head) or vehicle. Five days later, mice received an intravenous injection of C.E.R.A. (10 μg/kg), C-C.E.R.A which is non-erythropoietic carbamylated derivatives of C.E.R.A. and confirmed lacking bioactivity in the in vitro hematopoiesis bioassay (10 μg/kg), or vehicle. Serum hepcidin levels and hematopoietic parameters were determined by LC-MS/MS and micro cell counter at day0, 2, 5 and 8 after intravenous treatment.
Results:C.E.R.A. suppressed serum hepcidin levels and increased reticulocyte numbers at day5. C.E.R.A. with iron pretreatment decreased hepcidin levels although the baseline of hepcidin levels increased, and reticulocyte numbers were also increased at day5.In contrast, no changes were observed in hepcidin levels and reticulocyte numbers by C-C.E.R.A with or without iron pretreatment.
Conclusions:C.E.R.A. administration suppressed serum hepcidin levels, while C-C.E.R.A. did not change hepcidin levels with or without iron intervention. These results suggest that C.E.R.A. treatment down-regulates serum hepcidin levels through activation of erythropoiesis.

前へ戻る